BridgeBio Pharma Inc vs Nasdaq100 ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Nasdaq100 ETF trades at $722.65. Which is the better fit depends on your goals.
| BBIO | QQQ | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $746.16 |
52-Week Low | $47.29 | $558.34 |
Enterprise Value | $18.16B | — |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
QQQ trades at $723.03, up 1.17% with strong bullish momentum from moving averages and institutional buying interest. The ETF shows technical strength with a bullish overall signal, though RSI_6 at 88.85 indicates potential near-term overbought conditions. Recent news highlights ongoing institutional accumulation and positive momentum in Nasdaq-100 components.
Outlook remains positive given strong technical momentum and institutional support, though elevated short-term RSI suggests potential consolidation. Key risks include expense ratio comparisons with QQQM and tech sector concentration. Analyst consensus is divided with 50% buy and 50% sell ratings.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →